LONDON, England—Use of the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone cuts the risk of worsening HF events and cardiovascular mortality in patients who have heart failure with ...

The FINEARTS-HF trial showed that in patients with symptomatic HF with preserved or mildly reduced LVEF, finerenone resulted in a lower composite rate of worsening HF events and CV death compared with ...

Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and ...

According to Stefan Anker, MD, PhD (Charité Universitätsmedizin Berlin, Germany), who presented RESHAPE-HF2 at ESC, the results are a clear win for the MitraClip (Abbott), which was superior to OMT ...

Finerenone reduced the risk of cardiovascular (CV) death and total heart failure (HF) events in patients with HF with mildly reduced or preserved ejection fraction, according to results from a phase 3 ...